Sanofi part­ners with Syn­thekine in im­munol­o­gy race

Syn­thekine is team­ing up with Sanofi in a $40 mil­lion-plus col­lab­o­ra­tion to de­vel­op IL-10 re­cep­tor ag­o­nists for au­toim­mune and in­flam­ma­to­ry dis­eases.

The cy­tokine-fo­cused biotech will re­ceive the $40 mil­lion up­front with the po­ten­tial for undis­closed ad­di­tion­al pre­clin­i­cal, de­vel­op­ment, reg­u­la­to­ry and com­mer­cial mile­stones, as well as tiered roy­al­ties on net sales. Sanofi will take over clin­i­cal and com­mer­cial ac­tiv­i­ties for se­lect­ed ag­o­nists.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER